高磷血症 中国就医指南

Hyperphosphatemia is a metabolic disorder characterized by elevated serum phosphate levels (>4.5 mg/dL or >1.45 mmol/L in adults), commonly encountered in endocrinology and nephrology practice. It arises primarily from impaired renal phosphate excretion—most frequently in chronic kidney disease (CKD) stages 4–5—though it may also result from excessive phosphate intake (e.g., via enemas, supplements, or parenteral nutrition), cellular phosphate shifts (e.g., tumor lysis syndrome, rhabdomyolysis), or dysregulated hormonal control involving parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), and vitamin D metabolism. In CKD, declining glomerular filtration rate reduces phosphate clearance, while secondary hyperparathyroidism and FGF-23 resistance further disrupt phosphorus homeostasis. Less common causes include hypoparathyroidism, acromegaly, and vitamin D intoxication. Epidemiologically, hyperphosphatemia affects approximately 30–50% of patients with stage 4–5 CKD and up to 70% of those on maintenance hemodialysis; its prevalence rises sharply with advancing renal dysfunction. Risk factors extend beyond CKD to include advanced age, diabetes mellitus, cardiovascular disease, malnutrition-inflammation complex, use of phosphate-containing medications (e.g., laxatives, antacids), and low dietary adherence to phosphate-restricted regimens. Untreated or poorly controlled hyperphosphatemia contributes significantly to vascular calcification, left ventricular hypertrophy, increased fracture risk, and accelerated progression of CKD—ultimately elevating all-cause and cardiovascular mortality. Quality of life is markedly compromised: patients report persistent fatigue, pruritus, muscle cramps, bone pain, cognitive fog, and sleep disturbances. Psychosocial burden includes anxiety about dialysis adequacy, dietary restrictions limiting social eating, and stigma associated with visible complications like calciphylaxis or skin necrosis. Early detection via routine serum electrolyte panels and proactive management—including dietary counseling, phosphate binders, and optimization of dialysis—are essential to mitigate morbidity and preserve functional independence. Multidisciplinary care involving endocrinologists, nephrologists, dietitians, and pharmacists improves long-term outcomes and patient-reported well-being.

# 高磷血症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：慢性肾病3–5期非透析患者、原发性甲状旁腺功能亢进轻症者、药物性高磷血症（如过量维生素D摄入）

• •饮食干预+磷酸盐结合剂：碳酸钙（国产）、司维拉姆（进口）、碳酸镧（高端）

• •基础检验监测：血磷、钙、iPTH、肾功能（肌酐、eGFR）、ALP

二、手术/介入治疗方案

适用人群：继发性/三发性甲状旁腺功能亢进伴顽固性高磷血症（iPTH >800 pg/mL，影像学证实腺瘤或增生）

• •甲状旁腺切除术（PTX）：开放或微创腔镜下全切+自体移植

- 术前检查（颈部超声、99mTc-MIBI显像、心肺评估）：1,800–3,500元

三、特殊复杂方案

适用场景：透析依赖型终末期肾病合并血管钙化、难治性高磷（血磷持续>2.1 mmol/L）

• •血液透析联合高通量膜+在线置换+司维拉姆缓释片强化方案

四、方案快速选择指南

• •预算有限（≤5,000元/年）：首选饮食管理+国产碳酸钙+季度监测
• •中等预算（1–3万元/年）：升级为司维拉姆+规范iPTH随访
• •急重症/并发症风险高：立即启动PTX评估，避免心血管事件恶化